<DOC>
	<DOC>NCT02363868</DOC>
	<brief_summary>The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.</brief_summary>
	<brief_title>Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Age &gt;18 years International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9 CM) code for CML (205.1x) At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013 Continuous eligibility for the 6 months pre and postindex date (defined as the date of first fill for dasatinib or nilotinib) History of bone marrow or stem cell transplant as identified in the 6 month preperiod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>